RSS

ADC Biotechnology

Oncology company ADC Bio has secured £2.5 million of additional funding to help it achieve business targets, the company has announced. Read more

News

ADC Biotechnology has predicted that the next crucial phase of innovation to optimise and streamline production processes of antibody drug conjugates will be designed at the clinical development stage by specialist, ADC focused service providers Read more

News

Innovative biotechnology company, ADC Biotechnology, has secured £1.14 million in funding from Downing LLP to assist the company in its US expansion and aid in the development of an advanced bioconjugation method. Read more

News

Biotechnology company, ADC Biotechnology, has announced that it is developing a new ‘downstream bioconjugation’ method that will enable conjugation and antibody purification to be performed concurrently. Read more

News

A partnership agreement has been signed by specialist antibody drug conjugate (ADC) contract services company, ADC Biotechnology, and multi-disciplined engineering specialists, WHP, for construction of a dedicated bioconjugation facility. Read more

News

Experts from biotech company ADC Biotechnology, have issued a warning that poor aggregation will cause problems in the antibody-drug conjugate (ADC) pipeline, with millions being wasted in development costs. Read more

News

ADC Biotechnology has secured investment for an $11 million bioconjugation facility, to be constructed at its new site in Deeside, North Wales, UK. Read more

News